UBS Group reissued their buy rating on shares of Bayer (FRA:BAYN) in a report released on Monday morning, www.boersen-zeitung.de reports.
BAYN has been the topic of several other reports. S&P Global set a €126.00 ($150.00) price objective on Bayer and gave the company a buy rating in a research note on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) target price on Bayer and gave the stock a buy rating in a report on Wednesday, November 29th. DZ Bank reissued a buy rating on shares of Bayer in a report on Monday, December 11th. equinet set a €118.00 ($140.48) target price on Bayer and gave the stock a buy rating in a report on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) target price on Bayer and gave the stock a buy rating in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of €121.67 ($144.84).
Shares of Bayer (FRA BAYN) opened at €103.16 ($122.81) on Monday. Bayer has a 12 month low of €100.60 ($119.76) and a 12 month high of €123.82 ($147.40). The firm has a market capitalization of $85,640.00 and a P/E ratio of 27.66.
COPYRIGHT VIOLATION NOTICE: “UBS Group Reaffirms Buy Rating for Bayer (BAYN)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/18/ubs-group-reaffirms-buy-rating-for-bayer-bayn.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.